ALZ BTA Stock Overview

A biopharmaceutical company, develops immunotherapies treatment for Alzheimer’s disease in Sweden. More details

ALZ BTA fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Risk Analysis

Earnings are forecast to decline by an average of 35.4% per year for the next 3 years

Shares are highly illiquid

Shareholders have been substantially diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

+ 2 more risks

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Alzinova AB (publ) Competitors

Price History & Performance

Summary of share price highs, lows and changes for Alzinova
Historical stock prices
Current Share Price	SEK 1.77
52 Week High	SEK 2.10
52 Week Low	SEK 1.70
Beta	1.24
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-12.38%

Recent updates

Shareholder Returns

	ALZ BTA	SE Biotechs	SE Market
7D	-5.9%	1.4%	0.5%
1Y	n/a	-2.7%	-3.6%

Return vs Industry: Insufficient data to determine how ALZ BTA performed against the Swedish Biotechs industry.

Return vs Market: Insufficient data to determine how ALZ BTA performed against the Swedish Market.

Price Volatility

Is ALZ BTA's price volatile compared to industry and market?
ALZ BTA volatility
ALZ BTA Average Weekly Movement	n/a
Biotechs Industry Average Movement	10.0%
Market Average Movement	6.8%
10% most volatile stocks in SE Market	13.7%
10% least volatile stocks in SE Market	4.2%

Stable Share Price: ALZ BTA's share price has been volatile over the past 3 months compared to the Swedish market.

Volatility Over Time: Insufficient data to determine ALZ BTA's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2011	5	Tord Labuda	www.alzinova.com

Alzinova AB (publ), a biopharmaceutical company, develops immunotherapies treatment for Alzheimer’s disease in Sweden. Its lead product candidate is ALZ-101, an active therapeutic oligomer-specific vaccine for the treatment of Alzheimer’s disease, which has completed part A of phase 1b study; and ALZ-201, a monoclonal antibody that neutralizes the toxic oligomers. The company is developing a humanized version of ALZ-201 in patients with Alzheimer’s disease that is in phase 1 clinical study.

Alzinova AB (publ) Fundamentals Summary

How do Alzinova's earnings and revenue compare to its market cap?
ALZ BTA fundamental statistics
Market cap	SEK 186.53m
Earnings (TTM)	-SEK 21.27m
Revenue (TTM)	SEK 20.05m

9.3x

P/S Ratio

-8.8x

P/E Ratio

Is ALZ BTA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ALZ BTA income statement (TTM)
Revenue	SEK 20.05m
Cost of Revenue	SEK 0
Gross Profit	SEK 20.05m
Other Expenses	SEK 41.32m
Earnings	-SEK 21.27m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

Aug 21, 2025

Earnings per share (EPS)	-0.20
Gross Margin	100.00%
Net Profit Margin	-106.06%
Debt/Equity Ratio	0.7%

How did ALZ BTA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/19 08:56
End of Day Share Price	2025/05/19 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Alzinova AB (publ) is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Ludvig Svensson	Carnegie Commissioned Research
Ludvig Svensson	Penser Access
Maria Karlsson Osipova	Penser Access

Alzinova OM:ALZ BTA Stock Report